^
Association details:
| Biomarker: | CD20 positive |
|---|---|
| Cancer: | Follicular Lymphoma |
| Drug: | MB-106 (CD20-targeted CAR-T immunotherapy) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
IMMUNOTHERAPY USING A 3RD GENERATION CD20 TARGETED CAR T-CELL (MB-106) FOR TREATMENT OF B-CELL NON-HODGKIN LYMPHOMA (B-NHL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Published date:
05/12/2021
Excerpt:
Pts with relapsed CD20+ B-cell malignancies are eligible...Overall response rate (ORR) was 92% (11/12) with a complete response (CR) rate of 58% (7/12)...In FL pts (n=9), ORR and CR were 89% (8/9) and 67% (6/9), respectively.
Secondary therapy:
cyclophosphamide + fludarabine oral
Trial ID:
